2020
VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study
Madeeva D, Christian J, Goshua G, Chun H, Lee A, Pine A. VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study. Blood 2020, 136: 34-35. PMCID: PMC8330245, DOI: 10.1182/blood-2020-142917.Peer-Reviewed Original ResearchVWF/ADAMTS13 ratioVon Willebrand factorADAMTS13 ratioVenous thrombosisNeutrophil activationCOVID-19Severe COVID-19 diseaseVWF activityNon-ICU unitsPathogenesis of coagulopathySeverity of coagulopathyAbsolute neutrophil countInstitutional review board approvalMarkers of inflammationIntensive care unitCross-sectional studyPotential therapeutic targetSodium citrate tubesReview board approvalSignificant correlationCOVID-19 diseasePossible mechanistic linkImmune system effectorsNeutrophil indexPertinent patient information
2018
Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment
Juthani P, Ahmed D, Ahmed O, Bona R, Neparidze N, Lee A. Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment. Blood 2018, 132: 5810. DOI: 10.1182/blood-2018-99-119418.Peer-Reviewed Original ResearchVenous thromboembolismVTE patientsPrevention of VTESymptoms of VTERecurrent venous thromboembolismDeep venous thrombosisRandomized control trialLong-term managementOnline health educationMost patientsPulmonary embolismAdult patientsHospitalized patientsOncology providersVenous thrombosisHematology clinicCancer HospitalMedication adherenceOutpatient clinicTreatment optionsPatient interviewsPhysician interviewsMalignant hematologyPatient educationPreventable deaths